title: The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.
abstract: The Cell Cycle Profiling - Risk Score (C2P-RS) based on CDK1 and CDK2 specific activities was significantly associated with relapse in breast cancers. We evaluated the prognostic value of the C2P-RS classification using a Japanese cohort including node-negative, hormone receptor-positive breast cancers treated with adjuvant endocrine therapy alone as systemic therapy. Of 266 patients, 22 (8.3%) relapsed within 5 years after surgery. The distribution of each C2P-RS group was 71.8% in the low group, 12.0% in the intermediate group, and 16.2% in the high group. The 5-year relapse-free survival rate in the low C2P-RS group (97.3%) was significantly higher than that in the intermediate C2P-RS group (84.3%) or the high C2P-RS group (74.4%) (P < 0.001). The univariate analysis demonstrated that age, tumor size, histologic grade, and HER2 had no significant correlations with relapse but the C2P-RS classification (P < 0.001) and Ki-67 (P = 0.009) were significantly associated with relapse. Multivariate analysis showed only that the C2P-RS classification was a significant independent prognostic indicator. The C2P-RS classification might be a significant predictor of earlier recurrence in node-negative, hormone receptor-positive breast cancers treated with endocrine therapy.
authors.affiliation: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
authors.forename: Seung Jin
authors.initials: SJ
authors.lastname: Kim
authors.affiliation: Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
authors.forename: Norikazu
authors.initials: N
authors.lastname: Masuda
authors.affiliation: Department of Breast and Endocrine Surgery, Osaka Koseinenkin Hospital, Osaka, Japan.
authors.forename: Fumine
authors.initials: F
authors.lastname: Tsukamoto
authors.affiliation: Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Inaji
authors.affiliation: Division of Pathology, The Cancer Institute of Japan Foundation for Cancer Research, Tokyo, Japan.
authors.forename: Futoshi
authors.initials: F
authors.lastname: Akiyama
authors.affiliation: Department of Breast and Thyroid Surgery, Kawasaki Medical School, Okayama, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sonoo
authors.affiliation: Department of Breast and Thyroid Surgery, Kawasaki Medical School, Okayama, Japan.
authors.forename: Junichi
authors.initials: J
authors.lastname: Kurebayashi
authors.affiliation: Department of Surgery, Osaka Police Hospital, Osaka, Japan.
authors.forename: Katsuhide
authors.initials: K
authors.lastname: Yoshidome
authors.affiliation: Department of Pathology, Osaka Police Hospital, Osaka, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Tsujimoto
authors.affiliation: Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takei
authors.affiliation: Department of Pathology, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Shinobu
authors.initials: S
authors.lastname: Masuda
authors.affiliation: Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan.
authors.forename: Seigo
authors.initials: S
authors.lastname: Nakamura
authors.affiliation: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. Electronic address: noguchi@onsurg.med.osaka-u.ac.jp.
authors.forename: Shinzaburo
authors.initials: S
authors.lastname: Noguchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D016203:CDC2 Protein Kinase; D002453:Cell Cycle / Q000235:genetics / Q000502:physiology*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D051357:Cyclin-Dependent Kinase 2 / Q000235:genetics / Q000378:metabolism*; D018844:Cyclin-Dependent Kinases / Q000235:genetics / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000201:enzymology / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies; D012306:Risk; D055815:Young Adult
chemical_list: D018931:Antineoplastic Agents, Hormonal; D016203:CDC2 Protein Kinase; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C528899:CDK1 protein, human; C495894:CDK2 protein, human
keywords: Breast cancer; CDK1; CDK2; Prognosis; Tumor growth speed